Table 3.

Risk factors for APOs: multivariate analysis

Variables	Model 1a
	Crude OR (95% CI)	aOR (95% CI)	P-value
Age at pregnancy	0.9 (0.9, 1.0)	1.0 (0.9, 1.1)	0.45
DORIA/Zen remission	0.5 (0.2, 1.1)	0.5 (0.2, 1.2)	0.11
SLICC-Damage Index (per 1-unit increase)	1.9 (1.2, 3.0)	1.8 (1.1, 2.9)	0.02
Positive LA in the 1st trimester	5.2 (2.4, 11.5)	4.2 (1.8, 9.7)	0.001

^aMultivariate analysis performed on complete cases for the tested variables: n = 230. aOR: adjusted odds ratio; LA: lupus anticoagulant; OR: odds ratio. Age at pregnancy was also forced into the analysis, as a known risk factor for APO. We included LA, and because of high collinearity, we excluded associated APS, at least one positive aPL test and treatments such as low-dose aspirin and low molecular weight heparin (as most women with APS or carrying aPL were treated with these drugs) from our regression models. Finally, we excluded prednisone dose, immunosuppressants, SLEPDAI, hypocomplementemia and anti-dsDNA from both models, as both the DORIA/Zen definition of remission and LLDAS are composite scores that already include these factors (see Supplementary Material, available at Rheumatology online). Bold text highlights significance.